Complement 3 Glomerulopathy Market Players:
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Apellies Pharmaceutical
- Amyndas Pharmaceuticals SA
- Kira Pharmaceuticals
- Alexion Pharmaceuticals Inc.
- Omeros Corporation
- Amgen Inc.
- Sobi®
- Boehringer Ingelheim International GmbH.
- AstraZeneca
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of complement 3 glomerulopathy is estimated at USD 9.75 billion.
The global complement 3 glomerulopathy market size crossed USD 9.51 billion in 2025 and is likely to register a CAGR of around 2.8%, exceeding USD 12.53 billion revenue by 2035.
North America complement 3 glomerulopathy (c3g) market will hold more than 36% share, driven by rising incidence of kidney disorders and growing hospital population, forecast period 2026–2035.
Key players in the market include Novartis AG, Apellies Pharmaceutical, Amyndas Pharmaceuticals SA, Kira Pharmaceuticals, Alexion Pharmaceuticals Inc., Omeros Corporation, Amgen Inc., Sobi, Boehringer Ingelheim International GmbH., AstraZeneca.
